StockData
Immuneering Corp logo

Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30
$3.50+0.04 (+1.16%)

Close on Nov 18, 2026Market cap $226.67MP/E –Yield –

Immuneering revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Immuneering's revenue for the twelve months ending Dec 31, 2023 was $0, down 100.0% year over year. For fiscal 2023 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$316.95K-84.8%
FY2021Dec 31, 2021$2.08M-10.0%
FY2020Dec 31, 2020$2.31M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$455-99.8%
Q3 FY2022Sep 30, 2022$38.38K-92.0%
Q2 FY2022Jun 30, 2022$94.42K-85.7%
Q1 FY2022Mar 31, 2022$183.70K-75.4%
Q4 FY2021Dec 31, 2021$189.59K-71.5%
Q3 FY2021Sep 30, 2021$482.13K-29.4%
Q2 FY2021Jun 30, 2021$660.04K+37.3%
Q1 FY2021Mar 31, 2021$748.20K–
Q4 FY2020Dec 31, 2020$665.08K–
Q3 FY2020Sep 30, 2020$682.57K–
Q2 FY2020Jun 30, 2020$480.84K–

More Immuneering figures

See a number that looks wrong?